-
Within half a month, 4 new Chinese medicine drugs were approved for marketing
Time of Update: 2023-02-01
1 New Traditional Chinese Medicine Linggui Shugan Granules Launched On December 28, the State Medical Products Administration approved the listing of Kangyuan Pharmaceutical's Class 3.
1 New Traditional Chinese Medicine Linggui Shugan Granules Launched On December 28, the State Medical Products Administration approved the listing of Kangyuan Pharmaceutical's Class 3.
-
Bio4T2 announces CAR-T vaccination for the first patient
Time of Update: 2023-02-01
js?cdnversion='+~(-new Date()/36e5)];Bio4t2 inoculated the first patient with T cells containing chimeric antigen receptors (CARs), targeting BT-001 antigen overexpression present in multiple types of solid tumors.
js?cdnversion='+~(-new Date()/36e5)];Bio4t2 inoculated the first patient with T cells containing chimeric antigen receptors (CARs), targeting BT-001 antigen overexpression present in multiple types of solid tumors.
-
Qilu Pharmaceutical's ophthalmic medication pipeline has ushered in a new member!
Time of Update: 2023-02-01
News on January 12, Qilu Pharmaceutical issued an announcement that the company's brimonidine timolol eye drops (including multi-dose and single-dose two packaging specifications) were approved for marketing by the National Medical Products Administration and deemed to have passed the consistency evaluation, of which the single-dose packaging is exclusively listed in China.
-
Innovent announces the completion of the first dose of mazdutide (IBI362) in a Phase III clinical study (DREAMS-2) in subjects with type 2 diabetes in China
Time of Update: 2023-02-01
, announced: glucagon-like peptide-1 receptor (GLP-1R) / glucagon receptor, GCGR) dual agonist mazdutide (R&D code: IBI362) was administered in a multicenter, randomized, dulaglutide-controlled phase III clinical study (DREAMS-2) in subjects with type 2 diabetes in China.
-
In less than a month, another subsidiary of this pharmaceutical company will be spun off and listed!
Time of Update: 2023-02-01
According to public information, the listed Kelun Pharmaceutical business spans the fields of pharmaceutical research and development, drug manufacturing and commercial circulation, and is engaged in the research and development, production and sales of infusion products, innovative drugs, generic drugs and antibiotic intermediates.
-
CSPC's new drug has been approved for clinical trials, and its product pipeline will be further enriched
Time of Update: 2023-02-01
Under the normalization of centralized procurement, the competition in the generic drug business of traditional pharmaceutical companies has become increasingly fierce, and many companies have realize
-
Two multinational pharmaceutical companies invested heavily in acquisitions, both with a transaction value of more than US$1 billion
Time of Update: 2023-02-01
Therefore, in the future, in the market environment of the overall valuation of innovative drugs, it may bring more acquisition opportunities for multinational pharmaceutical companies.
Therefore, in the future, in the market environment of the overall valuation of innovative drugs, it may bring more acquisition opportunities for multinational pharmaceutical companies.
-
Merck released a statement on the new crown drug monoravir capsules
Time of Update: 2023-02-01
Merck China said that Molnupiravir capsules (trade name: Leadury ®/LAGEVRIO)® is an anti-new coronavirus oral drug jointly developed by Merck and Ridgeback Biotechnology, which was approved by China's National Medical Products Administration on December 29, 2022.
-
Technical factors for the development of nasal disease vaccines
Time of Update: 2023-02-01
2. Safety and weak immunogenicity of nasal epidemic seedlings Intranasal influenza vaccinations are generally considered safe and effective, but there have been examples of delisting due to related adverse events, such as the 2001 delisting of Nasalglu produced by Berna Biotech due to induced Bell's palsy.
-
Shanton has screened the first subjects in the Phase II.b study of SAP-001 refractory/tophi gout
Time of Update: 2023-02-01
js?cdnversion='+~(-new Date()/36e5)];Shanton Pharma, a clinical-stage biotechnology company that has developed a breakthrough treatment for patients with refractory/tophi gout, announced the launch of the RID GOUT study, a Phase IIb study of Shanton's investigational drug, SAP-001, on January 9.
-
Clinical trials of new drugs for skin diseases under development have achieved milestones, and Tekoro has bucked the trend to win tens of millions of Series A+ financing
Time of Update: 2023-02-01
On January 13, Jiaxing Tekoro Biotechnology Co. , Ltd. (hereinafter referred to as "Tekoro"), which focuses on the research and development of new skin drugs, announced that it has recently completed
-
"Innovative drug brother" stormed the more than 70 billion diabetes drug market
Time of Update: 2023-02-01
It is reported that on January 13, the Center for Drug Evaluation (CDE) of the State Medical Products Administration of China announced that Shengdi Pharmaceutical, a subsidiary of Hengrui Pharmaceutical, has submitted new drug marketing applications for repagliptin metformin tablets (I.
-
Guangshengtang anti-new coronavirus oral small molecule class of innovative drugs Taizhongding completed and obtained the clinical study (IIT) summary report initiated by the investigator
Time of Update: 2023-02-01
js?cdnversion='+~(-new Date()/36e5)];In order to evaluate the efficacy and safety of GST-HG171 (proposed Chinese generic name "Taiatevir") combined with ritonavir (collectively referred to as "Taizhongding") in patients with the new crown of Fujian Guangsheng Zhonglin Biotechnology Co.
-
Extracellular vesicles-loaded protein replacement therapies with mRNA: A novel method of mRNA delivery opens the door to other gene therapies
Time of Update: 2023-02-01
According to the article, in order to solve the loss of collagen caused by aging in the skin, the relevant team has created a new gene therapy platform based on non-viral vector technology and reproducible administration, using extracellular vesicles (EVs) to deliver the mRNA encoding collagen to skin cells, where mRNA can encode and express the corresponding protein, thereby functioning.
-
Johnson & Johnson will open the "buy, buy, buy" mode in the fields of eye care, orthopedics and cardiovascular!
Time of Update: 2023-02-01
Johnson & Johnson CEO Joaquin Duato said the company will look for opportunities to merge or acquire companies to add value to its focus areas such as eye care, surgical robotics, orthopedics and cardiovascular products.
-
Kangchen Pharmaceutical KC1036 entered the phase II clinical study of thymic tumor
Time of Update: 2023-02-01
js?cdnversion='+~(-new Date()/36e5)];Beijing Kangchen Pharmaceutical Co.
js?cdnversion='+~(-new Date()/36e5)];Beijing Kangchen Pharmaceutical Co.
js?cdnversion='+~(-new Date()/36e5)];Beijing Kangchen Pharmaceutical Co.
js?cdnversion='+~(-new Date()/36e5)];Beijing Kangchen Pharmaceutical Co.
(hereinafter referred to as the "Company") recently announced the phase II clinical trial information of KC1036 for the treatment of advanced thymic tumor patients on the drug clinical trial registration and information disclosure platform of the State Medical Products Administration.
-
Due to the surge in production and sales of intermediates, this pharmaceutical company will achieve a double increase in profit in 2022!
Time of Update: 2023-02-01
According to the data, the main business of East Asia Pharmaceutical is pharmaceutical manufacturing business, and the main products are antibiotics, digestive system, antiviral, cardiovascular, antipyretic and analgesic drugs 。 At present, the antibiotic drugs in production mainly include amoxicillin, clavulanate potassium dispersible tablets, azithromycin dispersible tablets, azithromycin for injection, roxithromycin capsules, cefzoxime sodium for injection, etc.
-
Sartorius Double 11 Promotion Consumables Special Offer Full of Gifts
Time of Update: 2023-01-06
11. 10-11. 11Double 11 promotion is about to end, and it's too late if you don't stock up on consumables Sartorius brand feedback day consumables promotion double benefits Ultrafiltration, filtration
-
77.2% of patients achieved objective remission, and the results of the new drug QL1706 for the treatment of cervical cancer with Qilu combination antibody were announced
Time of Update: 2023-01-06
This study aimed to assess the safety and efficacy of QL1706 in combination with paclitaxel-cisplatin/carboplatin plus or without bevacizumab for the first-line treatment of relapsed or metastatic cervical cancer.
-
New adjuvant new crown pneumonia epidemic Miao ReCOV updated a number of overseas clinical research progress
Time of Update: 2023-01-06
3. ReCOV primary immunization and sequential booster immunization can induce high levels of neutralizing antibodies against Omicron variants.
3. ReCOV primary immunization and sequential booster immunization can induce high levels of neutralizing antibodies against Omicron variants.
